RxDoctor Payments Data

Monica Bradshaw

Primary Care · Maiden, NCNPI 1043991680

Payments from drug & device makers

$669in general payments, 2019–2025

Across 37 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$185
  • AbbVie$88
  • Lilly USA, LLC$60
  • Xeris Pharmaceuticals, Inc.$52
  • Dexcom, Inc.$49
  • Phathom Pharmaceuticals, Inc.$39
  • plus $196 from 8 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$669 in reported general payments places this provider in the 60th percentile of 236 primary care providers in North Carolina.

See all primary care providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,344
Medicare patients
43
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase14$402,254
OzempicSemaglutide50$49,329
EliquisApixaban40$36,951
RybelsusSemaglutide21$19,956
JardianceEmpagliflozin24$18,445
MounjaroTirzepatide16$16,699
FarxigaDapagliflozin Propanediol12$6,571
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,191
Tresiba Flextouch U-100Insulin Degludec13$4,410
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,661
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,908
Albuterol Sulfate HfaAlbuterol Sulfate67$1,623
Omeprazole128$1,423
Gabapentin82$1,132
Atorvastatin Calcium174$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$27$402,25414 claims
Novo NordiskOzempic, Rybelsus$185$69,28571 claims
PfizerEliquis$16$36,95140 claims
Boehringer IngelheimJardiance$19$18,44524 claims
Lilly USA, LLCMounjaro$60$16,69916 claims
AstraZenecaFarxiga$16$6,57112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 236 primary care providers in North Carolina.

Other primary care in Maiden

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →